Prognostic Impact of Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients.

Mohamed Elbaiomy Salah ArefM El ZaafaranySara AtwaTamer AklWafaa El-BeshbishiShaimaa El-AshwahL IbrahimMohammed Sabry El-Ghonemy

Published in: Advances in hematology (2019)

We conclude that high LEF1 expression was a favorable prognostic marker which can define AML patient risk and outcome independent from assessing the serum galectin.3 level.

Keyphrases

poor prognosis
acute myeloid leukemia
end stage renal disease
binding protein
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
allogeneic hematopoietic stem cell transplantation
case report
transcription factor
patient reported outcomes